Cellular targets of the oncoproteins encoded by the cancer associated human papillomaviruses

Related Experiment Videos

P M Howley1, K Münger, H Romanczuk

  • 1Laboratory of Tumor Virus Biology, National Cancer Institute, Bethesda, Maryland 20892.

Princess Takamatsu Symposia
|January 1, 1991
PubMed

Insights

High-risk human papillomaviruses (HPVs) use E6 and E7 oncoproteins to inactivate tumor suppressor proteins pRB and p53, driving cervical cancer. This inactivation occurs through complex formation or degradation, crucial for HPV-driven carcinogenesis.

Area of Science:

  • Molecular Biology
  • Virology
  • Oncology

Background:

  • DNA tumor viruses encode oncoproteins that interact with cellular regulatory proteins to transform cells.
  • High-risk human papillomaviruses (HPVs), such as HPV-16 and HPV-18, are linked to anogenital carcinomas.
  • These HPVs express E6 and E7 oncoproteins, critical for cellular transformation.

Purpose of the Study:

  • To investigate the mechanisms by which HPV oncoproteins E6 and E7 contribute to cellular transformation.
  • To elucidate the roles of pRB and p53 tumor suppressor proteins in HPV-associated cervical carcinogenesis.

Main Methods:

  • Analysis of E7 oncoprotein interactions with the retinoblastoma protein (pRB).
  • Investigation of E6 oncoprotein complex formation with the p53 tumor suppressor.
  • Examination of pRB and p53 gene and protein status in HPV-positive and HPV-negative cervical cell lines.

Main Results:

  • High-risk HPV E7 proteins bind pRB with higher affinity than low-risk HPV E7 proteins.
  • High-risk HPV E6 oncoprotein promotes p53 degradation via the ubiquitin-dependent protease system.
  • HPV-positive cervical cancer cell lines showed normal pRB and low p53 levels, suggesting functional alteration by oncoproteins.
  • HPV-negative cervical carcinoma cell lines exhibited mutations in p53 and RB genes.

Conclusions:

  • Inactivation of pRB and p53 tumor suppressor functions is a key event in human cervical carcinogenesis.
  • HPV oncoproteins E6 and E7 achieve this inactivation through complex formation and protein degradation.
  • These findings highlight a novel mechanism for dominant oncoprotein action in cancer development.

Related Concept Videos